EGFR and nasopharyngeal carcinoma: Recent clinical trials showed that nimotuzumab (a humanized monoclonal antibody targeting EGFR) has certain advantages in treating patients with locally advanced NPC, or in combination with chemotherapy, radiotherapy, and CCRT for patients with recurrent or metastatic NPC (41–43).